We are faced with the generation of very large volumes of complex NGS data, which presents a huge challenge for its analysis, and with the question how we can derive a simple scientific interpretation and […]
As interest in microbiome is rapidly growing globally, the Greater Copenhagen region – spanning Eastern Denmark and the southernmost part of Sweden – offers international businesses and researchers a unique combination of a rich ecosystem […]
The regulatory environment for live biotherapeutic products is still uncertain globally, of course, but one booming area is the manufacturing of these products as they move through their clinical development process. Adrien Nivoliez, CEO of Biose Industrie reflects on […]
Every microbiome-focused company has its own approach for discovering drug candidates—but rarely is the mechanism of action for a live biotherapeutic product (LBP) known from the outset. Microbiome pharma company ImmunoBiome, however, uses a unique […]
With increasing evidence for microbial involvement in many human diseases, live biotherapeutic products (LBPs)—living microbes administered therapeutically—have emerged as a group of exciting new drug candidates. Although the LBP regulatory environment remains uncertain, companies all […]
Following Biofortis first paper The human microbiome: a global overview of clinical trials activity, this article compares the emergence of the human microbiome field with the rise of human genomics through a review on how […]
While“healthy” microbiome remains to be defined, microbiome disruption is associated with numerous diseases, offering new therapeutic opportunities if causalities are demonstrated. Europe is at the forefront of the understanding of the Microbiome and is well placed […]